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Symposium Articles 
From Bench to Society: Law and Ethics at the 
Frontier of Genomic Technology 
Jamie S. King* 
 
 
On February 8, 2013, the UCSF/UC Hastings Consortium on Law, 
Science, and Health Policy and the Hastings Law Journal co-sponsored a 
symposium titled From Bench to Society: Law and Ethics at the Frontier 
of Genomic Technology. The impetus behind this conference was to 
bring together leading national scholars trained in genetics, genetic 
counseling, medicine, law, philosophy, psychology, sociology, ethics, and 
public policy to spend the day examining the vast potential implications 
(both good and bad) of the next wave of major advances in genetic and 
genomic testing for patients, providers, their families, the practice of 
medicine, and society as a whole. We hoped to inspire the group to think 
collectively about what we can do now to glean all of the potential 
benefits we can from spectacular scientific achievements, such as whole 
genome sequencing, whole exome sequencing, and epigenetics, while 
simultaneously implementing safeguards to protect individuals and 
society from the challenges that lay ahead. The day was quite eye-
opening for audience members and panelists alike, and fostered 
numerous discussions and potential collaboration opportunities during 
breaks and the end of the day reception. 
The day began with an introduction to genetics and genomics by 
Professor Kelly Ormond, who provided the non-scientists in the room 
with a wonderful overview of everything from the basics of genetic 
science to recent developments in sequencing and targeted sequencing 
analysis. Professor Ormond’s presentation set the stage for subsequent 
discussions. 
We then moved into our first of three substantive panels, titled 
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Predictions of Future Health, which I moderated. This panel posed 
significant questions regarding the potential benefits and detriments of 
using whole genome sequencing to make predictions of future health 
states. Dr. Wylie Burke focused her presentation on the expansive set of 
information available through whole genome sequencing and the 
challenges of communicating that information to individuals. She also 
argued, as do she and her colleagues Susan Brown Trinidad and Ellen 
Wright Clayton in their Article in this issue, Seeking Genomic 
Knowledge: The Case for Clinical Restraint, that health care providers 
should only focus on genetic information that has sufficient clinical utility 
to guide medical decisions. This proposal would open the door to private 
companies that offer personal genetic information directly to consumers 
regarding a large portion of the human genome that so far reveals little 
actionable clinical information. Next, Dr. Mildred Cho presented 
evidence on how the implementation of genomics in clinical practice is 
being driven by forces other than the clinical judgment of clinicians. 
Further, her presentation explored the role that insurance, lack of 
comprehensive regulatory policy, commercialization, and particularly, 
intellectual property policy play in determining the use of genomic 
advances. Finally, Professor Mark Rothstein acknowledged that for 
symptomatic or high risk individuals, whole genome sequencing is a 
marvelous advance in diagnostic testing. He then argued his lecture titled 
The Case Against Precipitous, Population-Wide Whole Genome 
Sequencing, which explored the significant challenges associated with 
whole genome sequencing for asymptomatic individuals, including a lack 
of clinical utility, lack of available genetic counselors to help translate the 
data to patients, and a general lack of societal understanding of the 
implications of many genetic findings. This panel raised many questions 
regarding what information should be returned to individuals as a result 
of genetic sequencing. Many of these issues are addressed in the Article 
Return of Results in Genetic Testing: Who Owes What to Whom, When 
and Why? by Stephanie Alessi. 
After lunch, Dr. George Poste gave the keynote address titled 
Personalized (Precision) Medicine: Science, Law and Health Policy. Dr. 
Poste’s presentation provided a whirlwind view of the technological 
potential to offer precision medical care designed for individual patients, 
including the use of personal handheld mobile devices to gather and 
communicate health data to providers on a regular basis. He also noted 
the significant privacy, economic, regulatory, and translational challenges 
that access to both genomic information and the technological capability 
to provide that information to individuals will create. Dr. Poste’s keynote 
spurred many questions and much discussion regarding how best to 
address patient demand and offer clinically relevant information. 
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Following the keynote address, Professor Osagie Obasogie 
moderated our second substantive panel titled Individualized Medicine. 
Dr. Robert Nussbaum discussed the scientific and clinical challenges that 
exist in today’s relatively unregulated and privatized world of genetic and 
genomic research. Like Dr. Cho, he noted that the commercialization of 
clinical research and treatment has led to substantial inefficiencies in the 
system, including an inability to identify prior cases of rare genetic 
diseases. He argued for improved regulation of genetic tests and greater 
public access to genetic data. Next, Dr. Barbara Koenig gave a very 
interesting presentation from the perspective of an anthropologist 
examining the growth of the commercial genomic industry in the last few 
years, and the societal forces that have contributed to that growth. She 
argued that critical examination of genomics and its role in society is 
needed to properly address the societal changes that access to this 
technology portends. Finally, Professor Hank Greely examined the wide 
range of challenges that arise with personalized genomics, specifically the 
challenge associated with creating computer programs to analyze the 
genome and translate the sequence into meaningful information for 
patients. Professor Greely proposed the creation of an entity to 
continuously and simultaneously curate the medical literature and 
interpret both genetic variations to disease risk and the strength of the 
findings. This information could then be published on the Internet, 
subject to peer review and open comment. Such a tool could be used to 
continually update all clinicians and researchers with information on the 
relevance of certain genotypes. 
Our final panel of the day, moderated by Professor David Faigman, 
examined recent advances in behavioral genetics and its potential for use 
in legal settings. This panel was conducted in a Fred Friendly format, 
which gave all of our panelists, Professor Josh Buckholtz, Professor 
Deborah Denno, Professor Nita Farahany, and Dr. Taylor Smith the 
opportunity to answer all questions posed by Professor Faigman and the 
audience. This panel was the most lively of the day, and Professors 
Buckholtz, Denno, and Farahany engaged in a fascinating debate 
regarding the usefulness of behavioral genetics research and individual 
genotypes in criminal sentencing. Describing the use of genetics in 
criminal courts for mitigation purposes, Professor Farahany noted that it 
had not been very compelling. Professor Denno argued in favor of 
permitting genetics information that has been associated with certain 
behaviors to be used in death penalty sentencing. Her article in this issue 
critiques a study recently published in Science by Aspinwall, Brown, and 
Tabery titled The Double-Edged Sword: Does Biomechanism Increase or 
Decrease Judges’ Sentencing of Psychopaths? Further, Dr. Smith 
discussed the role of epigenetics in psychological and behavioral 
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disorders, and he and his coauthors, Matthew Maccani and Valerie 
Knopik, explore the use of epigenetic research in a legal and policy 
context in their Article in this issue titled Maternal Smoking During 
Pregnancy and Offspring Health Outcomes: The Role of Epigenetic 
Research in Informing Legal Policy and Practice. 
Overall, the day proved fascinating though daunting on many fronts. 
I invite you to view the conference on the UCSF/UC Hastings 
consortium webpage, as this brief introduction cannot begin to do it 
justice. The opportunities that we, as a society, will have to explore our 
genetic information, to have a better understanding of the role our 
genetics plays in the development of disease, and in some cases, behavior 
are unbounded. However, significant challenges will arise regarding how 
we analyze, translate, understand, and protect this information. A 
general consensus appeared to exist that genomic technology is coming 
at a pace that far exceeds our ability to address these challenges and that 
as a society, we are largely unprepared for its arrival. However, through 
interdisciplinary symposia like this one, we can improve our 
understanding of the implications of advances in genomics and ignite 
further discussions and collaborations on how to best handle the 
individual and societal risks associated with some of our greatest 
scientific achievements. 
 
 
